

Review: Gene therapy in animal models of autosomal dominant retinitis pigmentosa

Brian Rossmiller, Haoyu Mao, Alfred S. Lewin

Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL

Gene therapy for dominantly inherited genetic disease is more difficult than gene-based therapy for recessive disorders, which can be treated with gene supplementation. Treatment of dominant disease may require gene supplementation partnered with suppression of the expression of the mutant gene either at the DNA level, by gene repair, or at the RNA level by RNA interference or transcriptional repression. In this review, we examine some of the gene delivery approaches used to treat animal models of autosomal dominant retinitis pigmentosa, focusing on those models associated with mutations in the gene for rhodopsin. We conclude that combinatorial approaches have the greatest promise for success.

Vision is one of our most valuable senses, allowing for the detection of a single photon at night and high acuity perception in the day. Thus, retinal degenerative diseases can have a large impact on the quality of life. One such disease, retinitis pigmentosa (RP), is responsible for vision loss in 1 in 4,000 people worldwide [1]. As retinitis pigmentosa is initially a disease of the rod photoreceptors, vision loss is first perceived in the periphery and at night. In retinal images, dark pigmentary deposits termed “bone spicules” are observed [2,3]. As the rods continue to die, a paling of the optic nerve, spreading of pigmentary deposits, thinning of retinal vessels, and decrease in electroretinogram (ERG) response are observed [2,3]. Only after the loss of rods do the cones of the macula begin to die, causing near total blindness in afflicted individuals [2,3].

Retinitis pigmentosa is transmitted in autosomal dominant, autosomal recessive, sex-linked dominant, and sex-linked recessive modes of inheritance [3]. More than 30 genes and many different mutations, over 100 mutations in rhodopsin alone, have been associated with retinitis pigmentosa [4,5]. This genetic heterogeneity is associated with differences in rate and the extent of the degeneration. Accounting for 30%–40% of all cases of retinitis pigmentosa, autosomal dominant retinitis pigmentosa (ADRP) is the most common mode of inheritance and is the consequence of mutations in 24 known genes (Table 1) [6].

Currently, there are no effective treatments for ADRP. Nutritional therapy featuring vitamin A or vitamin A plus docosahexaenoic acid reduces the rate of degeneration in

some patients [7]. Retinal analogs and pharmaceuticals functioning as chaperones show some progress in protecting the retina in animal models [8-11], and several antioxidant studies have shown lipophilic antioxidant tauroursodeoxycholic acid (TUDCA), metallocomplex zinc desferrioxamine, N-acetylcysteine, and a mixture of antioxidants slow retinal degeneration in rodent rd1, rd10, and Q344ter models [12-15]. Although TUDCA is in clinical trials for other indications, it has not been tested in patients with retinal disease. A clinical trial is under way to test the efficacy of the protein deacetylase inhibitor valproic acid as a treatment for retinitis pigmentosa (Clinicaltrials). Valproic acid blocks T-type calcium channels and voltage-gated sodium channels [16], and is associated with significant side effects such as hearing loss and diarrhea. Therefore, the use of valproic acid as a treatment for retinitis pigmentosa has been questioned [17,18].

Rhodopsin mutations: Despite the range of genes responsible for ADRP, approximately 30% of ADRP arises from mutations in the rhodopsin gene [19], and therefore, we focus our attention on treatment of mutations affecting the rhodopsin gene (*RHO* in humans and *Rho* in mice). Numerous alterations in *RHO* cause ADRP (Figure 1; RetNet). These mutations do not localize to any specific regions of the protein, suggesting that functional and stable rhodopsin tolerates few amino acid changes. In fact, human rhodopsin protein differs at only 13 positions from the rabbit, 17 positions from the cat, and 18 positions from the mouse. The maximum sequence identity is ≥95% among all of these organisms. The consequences of particular mutations have been analyzed in transfected cells and animal models, sometimes with conflicting results [20]. Rods are also highly susceptible to changes in rhodopsin expression and translocation to the outer segment of photoreceptors, as rhodopsin composes greater than 90% of the outer segment protein [1,5,21-23].

Correspondence to: Alfred S. Lewin, Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32611; Phone: (352) 392-2617; FAX: (352) 273-6269; email: lewin@ufl.edu

TABLE 1. GENES AND LOCI ASSOCIATED WITH ADRP.

Protein	Gene	Location
Bestrophin-1	<i>BEST1</i>	11q13
Carbonic anhydrase IV	<i>CA4, RPI7</i>	17q23.2
Cone-Rod Homeobox	<i>CRX</i>	19q13.32
Fascin homolog 2	<i>FSCN2, RP30</i>	17q25.3
Guanylate cyclase activator 1B	<i>GUCA1B, RP48</i>	6q21.1
Inosine monophosphate dehydrogenase 1 kelch-like protein 7	<i>IMPDH1, RP10</i> <i>KLHL7, RP42</i>	7q32.1 7p15.3
Nuclear receptor subfamily 2 group E member 3	<i>NR2E3</i>	
Neural retina leucine zipper	<i>NRL, RP27</i>	14q11.2
OSBP-related protein 1	<i>ORP1, DCDC4A, RPI</i>	8q12.1
pre-mRNA processing factor 3	<i>PRPF3, RP18</i>	1q21.2
pre-mRNA processing factor 31 homolog	<i>PRPF31</i>	19q13.342
pre-mRNA processing factor 6	<i>PRPF6, rp60</i>	20q13.33
pre-mRNA processing factor 8	<i>PRPF8</i>	17.13.3
Peripherin 2	<i>PRPH2, RDS, RP7</i>	6q21.1
Rhodopsin	<i>RHO</i>	3q22.1
Retinal outer segment membrane protein 1	<i>ROM1</i>	11q12.3
Retinitis pigmentosa 1 protein	<i>RPI, LI</i>	8q23.1
Unknown	<i>RP63</i>	6q23
Retinitis pigmentosa 9 protein	<i>RP9</i>	7p14.3
Retinal pigment epithelium-specific protein	<i>RPE65, RP20</i>	1p31.2
Semaphorin	<i>SEMA4A, RP35</i>	1q22
Proto-oncogene tyrosine-protein kinase MER	<i>MERTK, RP33</i>	2q11.2
Topoisomerase I-binding arginine/serine-rich protein	<i>TOPORS</i>	9q21.1

Known gene and loci locations for ADRP causing mutations and associated proteins or loci names. References are at [RetNet](#).

ADRP mutations in rhodopsin have been placed into categories based on the mutations' impact on protein folding and trafficking. Class I mutations result in normal rhodopsin folding, but the protein is not efficiently transported to the outer segment and has constitutive activation or an increased transducin activation rate [24]. Mutations affecting the C-terminus of rhodopsin, such as P347S, fall into this class. Class II mutations result in opsin that folds improperly, is retained in the endoplasmic reticulum (ER), and does not reconstitute with the 11-cis-retinal chromophore [24,25]. Rhodopsin folding and function can be affected by alterations in post-translation modification sites for glycosylation and disulfide bond formation [21,26]. Mutations affecting glycosylation at N2 and N15 and the disulfide bond between C110 and C187 are known causes of ADRP [26-28]. The T17M mutation results in rapid degeneration especially evident in the inferior retina. In some cases, degeneration from this class can be slowed with restricted light exposure [29,30]. The most common class II mutation in *RHO* in North America

is P23H. P23H has been shown to be a target of the endoplasmic reticulum associated protein degradation (ERAD) effector valosin containing protein (VCP), a chaperone responsible for removing misfolded proteins from the ER for proteasomal degradation. In a rat model of ADRP, P23H rhodopsin stimulates the unfolded protein response [31,32]. Other mutations in *RHO* have been classified based on the stability of the protein or by the constitutive activation of the visual transduction pathway [24]. G90D, for example, leads to constitutive activation of transducin and causes congenital stationary night blindness.

Although ADRP mutations affect rod photoreceptors directly, they ultimately result in the death of cone photoreceptors and the loss of central vision. The mechanism by which *RHO* mutations cause cone cell death is not known, but several mechanisms have been proposed. These include (i) release of endotoxins, (ii) loss of rod trophic factors, (iii) loss of contact with the retinal pigment epithelium (RPE), (iv)


activation of Müller glial cells, (v) increased oxygen toxicity, and/or increased metabolic load [5,33].

Animal models of autosomal dominant retinitis pigmentosa: The need for an effective therapy for ADRP has led to the creation of several mammalian models, and the use of these models has aided in the ongoing development of treatments focusing on neurotrophic factors, gene suppression, and gene replacement using viral or non-viral delivery. Due to the high degree of sequence homology in rhodopsin, mutations affecting human families can often be studied in animals. Because of their genetic malleability, mice and rats provide the most common models with rhodopsin mutations, including P23H, T17M, P347S, and S334X, present on transgenes, leading to retinal degeneration at varying rates. Chemical mutagenesis has led to the isolation of mouse lines bearing other mutations at the *Rho* locus, and Sakami et al. have produced a line bearing P23H *Rho* knocked into the endogenous locus [34,35]. The canine model of ADRP has provided insight into the risks of clinical illumination and the benefits of neurotrophic factors as potential treatments

[36-39]. Porcine models of ADRP are also available. The size of the pig eye has lent it to testing of surgical treatments for ADRP such as retinal sheet transplants [40,41], but the large size of domestic swine make them difficult to work with as adults. Ross et al. have recently described an inbred line of miniature pigs bearing a human P23H transgene, and these may prove to be a tractable model [42].

Preclinical outcome measurements: Assessing the course of retinal degeneration and the success of treatment in rodent models of retinal disease employs some of the same technologies used to evaluate patients with retinitis pigmentosa: ERG, spectral domain optical coherence tomography (SD-OCT), and digital fundus imaging. In addition, light and electron microscopy on fixed tissue can be used to measure histopathology in animal models of ADRP.

Full-field ERG is typically used to assess retinal function in mouse and rat models of ADRP [22,43-46]. Because the retinas of these nocturnal rodents are rod-rich, dark-adapted (scotopic) ERG measurements are recorded, though light-adapted (photopic) ERG amplitudes may be affected in



models of cone-rod dystrophy or late in the course of RP models. Results are typically presented as a-wave and b-wave maximum amplitudes as a function of flash intensity or as a-wave and b-wave amplitudes as a function of time at a single flash intensity. Because the full-field ERG recordings measure the response of the whole retina, local improvements in retinal function resulting from localized gene delivery may be difficult to accurately measure. Because ERG responses from both eyes are typically recorded simultaneously, a sham-treated contralateral eye can be used as the control for eyes treated with gene therapy.

Visual function can also be evaluated with behavioral analysis [47]. Although the Morris water maze can be used in dim light to measure the recovery of rod function after gene therapy [48], optokinetic (OptoMotry™ CerebralMechanics, Lethbridge, AB, Canada) analysis has been used to measure visual acuity and contrast sensitivity in mice following gene therapy or cell transplantation therapy for retinal degeneration [49-51]. Since optokinetic measurements are performed in a lit room, they are primarily useful for measuring photopic function.

SD-OCT instruments have become widely used for assessing retinal degeneration in animal models in the past few years [49,52-55]. OCT is an interferometer-based imaging technology providing cross-sectional images of tissues transparent to infrared illumination. Instruments from Heidelberg Engineering or Bioptigen permit measurement of retinal thickness and of the thickness of the outer nuclear layer (ONL), which is often used to assess the survival of photoreceptor cells. The ONL is measured between highly reflective bands corresponding to the outer plexiform layer and the external limiting layer of the retina. SD-OCT permits the same cohort of animals to be followed longitudinally over the course of retinal degeneration and response to treatment. An added value of SD-OCT for preclinical gene therapy testing is that retinal detachment resulting from subretinal injections is readily detected, allowing these animals to be removed from the analysis.

Fundus imaging using film, and, more recently, digital imaging, has long been used to qualitatively monitor the course of retinal degeneration in patients and in research animals [56], and many of the mouse models of retinal degeneration were first recognized by fundus phenotype [57]. Some instruments used for SD-OCT are also capable of digital fundus imaging, and this is useful because both image modalities can be used in the same session of anesthesia. Unlike RP in humans, which is recognized by pigment deposition, mouse models of retinal degeneration are characterized by hypopigmented regions or spots. These regions

may become larger during the course of retinal degeneration, and this progression may be arrested with successful gene therapy [58].

Although SD-OCT provides a measurement of ONL thickness, SD-OCT does so only in the central 30% of the retina, so that light microscopy is necessary to assess retinal structure in the periphery. In addition, the photoreceptor outer and inner segments are not well resolved by SD-OCT, so that the structure and thickness of these layers must be measured by microscopy and morphometry. Typically, eyes are fixed in glutaraldehyde and paraformaldehyde, dehydrated, and then embedded in plastic or in paraffin. Sections are made along the vertical meridian through the optic nerve head, and the thickness of the retinal layers is measured at regular distances from the optic nerve head in the superior and the inferior retina [59].

Therapeutic approach: neurotrophic factors: Neurotrophic factors (NTFs) play a large role in the development and maintenance central nervous system including the retina. One RPE cell, for instance, contacts 40 cones and rods and secretes NTFs both to the choroid and the photoreceptors [6]. Rods also produce a neurotrophic factor, rod derived cone viability factor (RdCVF), a thioredoxin-like protein lacking the oxoreductase activity, that influences cone survival [60,61]. The injection of RdCVF protein in P23H rats increased cone density 19% [62]. RdCVF also increased the survival of retinal explants from *rdl* mice, an effect that could be blocked if RdCVF was immunodepleted [60]. Basic fibroblast growth factor (bFGF) comprises 22 types, but only bFGF2 has been shown to preserve photoreceptors in RCS rats for approximately two months [59]. Application of acidic fibroblast growth factor (aFGF) and bFGF in the subretinal space and the vitreous preserved ONL thickness in RCS rats with diminished RPE engulfment of photoreceptor outer segments [59]. Brain derived neurotrophic factor (BDNF) is expressed in many locations, including the brain, motor neurons, and the retina. When administered with other NTFs, including ciliary-derived neurotrophic factor (CNTF) and glial-derived neurotrophic factor (GDNF), BDNF increased photoreceptor preservation but caused the cells to revert to a more primitive state and reduced synthesis of rhodopsin [63,64]. Pigment epithelium derived factor (PEDF) is being studied for treatment of age-related macular degeneration and is known to be secreted by Müller glial cells and the RPE [65,66]. PEDF protects cells from glutamate toxicity and photoreceptors from excessive light. PEDF also slows degeneration in *rdl* mice. Two of the more promising NTFs, CNTF, and GDNF, have been delivered by gene transfer. These factors could promote cell survival in different forms

of ADRP and thus prolong useful vision and the window for therapeutic treatment.

Ciliary-derived neurotrophic factor: CNTF is a member of the interleukin-6 (IL-6) family of cytokines [67]. Its effectiveness is limited by a short half-life of 120–400 min, which rules out bolus injections [68]. Research has instead focused on a virally delivered CNTF gene or on mammalian cell lines encapsulated in an implantable device, NT-501 [67,68]. Mice transgenic for a dominant negative mutant (P216L) of rds/peripherin (*Prph2*) showed photoreceptor protection, but reduced ERG and decreased photoreceptor gene expression when injected with an adeno-associated virus (AAV) expressing a secreted form of CNTF in the subretinal space [69]. Loss of retinal function in *Prph2* mutant mice was also reported by Schlichtenbrede et al. [70]. CNTF delivered as a protein was beneficial in maintaining ONL thickness in rats bearing the S334X mutation of rhodopsin [71]. CNTF was even shown to cause regeneration of cone outer segments (OS). Liang and colleagues, also working with rats transgenic for S334X or P23H *RHO* and *Prph2*^{rd2/rd2} mice, had similar results, showing a preservation of retinal histology months after the photoreceptors began to degenerate [72]. A reduction in the ERG a-wave and b-wave responses and an increase in Müller glial cell activation were also noted. Similar results were also seen, using NT-501 during human phase I clinical trials [67].

Glial-derived neurotrophic factor: The benefits of GDNF, a member of the transforming growth factor-beta family, to the central and peripheral nervous system have been studied for years: GDNF prolongs dopaminergic neuron and dorsal root ganglion cell survival. GDNF and its receptors are naturally expressed in the retina [40]. AAV expression of GDNF, driven by a CMV enhancer/chicken beta-actin (CBA) promoter, slowed photoreceptor degeneration and maintained ONL thickness and ERG response in rats bearing a transgene containing an ADRP *RHO* mutation (S334X) [73]. There are several possible mechanisms for the protective effects of GDNF. First, GDNF may elicit effects through increases in the levels of other NTFs, including BDNF and fibroblast growth factor-2 [74,75]. Second, GDNF could protect the metabolically active retina from reactive oxygen species, already shown in kainate injected pyramidal neurons [76]. Since GDNF receptors are expressed on Müller glial cells but not in photoreceptors, GDNF probably protects photoreceptors indirectly, acting through Müller cells [40].

Retinas of rats treated with AAV-GDNF had no indication of inflammatory cell infiltration, no decrease in retinal ganglion cells, and no statistical effect on ERG response after 1 year of expression [77]. GDNF not only increased retinal

cell survival in vivo but also enhanced the survival of axotomized retinal ganglion cells and light response of transplanted retinal sheets [78,79]. Using the *Prph2*^{rd2/rd2} mouse model and the RCS rat model of retinal degeneration, Buch et al. showed that AAV-CBA-GDNF led to significant functional improvement based on ERG amplitudes and preservation of the ONL especially when combined with gene supplementation [80].

Neurotrophic factor disadvantages: Neurotrophic factors have the disadvantage of non-specific action. CNTF in the vitreous has demonstrated effects on retinal ganglion cells, Müller glial cells, astrocytes, and cone and rod photoreceptor cells [81-83]. CNTF has been shown to cause regeneration of cone outer segments but at the expense of rod function [83]. The knockdown of photoreceptor gene expression by CNTF is transient, and normal gene expression is detected when CNTF is no longer present. GDNF is also known to affect various cell types and possibly dose-dependent toxicity [84]. Application of neurotrophic factors as proteins could allow degeneration to be slowed until a long-term treatment has been administered.

Therapeutic approach: gene suppression and replacement: Although neurotrophic factors are aimed at preserving the photoreceptors without addressing the underlying mutation, more direct treatments including gene suppression or replacement are also being tested. Photoreceptors are sensitive to changes in rhodopsin levels, and overabundance of this protein can lead to retinal degeneration in mouse models [23,85]. In a transgenic mouse line, an excess of rhodopsin of only 23% was enough to cause RP-like retinal degeneration [86]. However, heterozygous null mutations in the mouse *Rho* gene result in a relatively normal retina at birth, with the length of rod outer segments approximately 60% that of *Rho*^{+/+} mice [87]. Similar to humans bearing heterozygous null mutations, *Rho*^{+/-} show a reduced response to light flash. Rhodopsin mutations, acting in a dominant negative manner, may be treatable simply through a DNA cassette expressing wild-type *RHO* [88,89]. With a single injection of AAV-transferred normal rhodopsin, 90% of the ERG response in a- and b-wave amplitudes can be preserved in P23H mice compared with P23H mice without treatment (Figure 2) [89]. Other mutations, however, may require suppression of the mutant gene plus provision of a wild-type replacement gene, especially since overexpression of rhodopsin can be toxic [86]. The methods for suppressing endogenous expression begin at the either the RNA or DNA level. RNA interference or ribozymes achieve suppression at the RNA level while advances in zinc finger transcription factors and endonucleases and transcription activator-like (TAL) effector nucleases could correct the mutations at the DNA level.




Figure 2. Improvement of electroretinography (ERG) response by single AAV injection of normal mouse rhodopsin cDNA (WT *Rho*) in P23H transgenic mice [89]. Bars represent the average of five scotopic ERG scans at 0 dB (2.6 cd (cd)-s/m²) a-wave response. **A:** and b-wave response. **B:** at 1 month and 6 months post injection. ERG amplitudes of 1 month uninjected P23H eyes were set as 100%. **A:** Compared with that of corresponding contralateral eyes, injection of AAV-*Rho* demonstrated a significant increase in a-wave amplitudes at both 1 month (122%) and 6 months (90%) time points. (* $p < 0.05$, $n = 6$). **B:** Compared with contralateral eyes, injection of WT *Rho* demonstrated the same significant increase in b-wave amplitudes as that of a-wave response at both 1 month (122%) and 6 months (90%) time points. (* $p < 0.05$, ** $p < 0.005$, $n = 6$). Although injection injury can induce protective cytokines such as CNTF, this effect peaks within a few days of injection and is complete before the first measurements were made.

Short interfering RNA: Therapeutic RNA interference (RNAi) employs three types of small RNA molecules: microRNA (miRNA), short hairpin RNA (shRNA), and short interfering RNA (siRNA). RNA interference with siRNA usually takes the form of direct treatment with modified double-stranded RNA (dsRNA) molecules, and requires repeated administration [90]. Therefore, this approach is not optimal for treating a chronic genetic disease, such as ADRP, though siRNAs are in clinical trials for age-related macular degeneration. Several groups are developing the use of RNAi for therapy for ADRP [91-97]. RNA interference was shown effective at knocking down the mutant mRNA and aiding in replacement with the wild-type gene [91,98] (Figure 3C).

Short hairpin RNA: Stably expressed shRNAs can be used to selectively suppress expression of mutant *RHO* if there is sufficient nucleotide difference with the wild-type gene. A more generally applicable approach, however, is to use RNAi to suppress the production endogenous rhodopsin and allow expression of a sequence-altered *RHO* gene that is resistant to the shRNA [97-99]. Millington-Ward and colleagues used a two-vector approach to treat a mouse model of ADRP: one virus to deliver the shRNA and one to deliver the replacement rhodopsin cRNA. They reported retention of an average b-wave response of 60 microvolts at 20 weeks post injection

in treated eyes, compared to a baseline response in control treated eyes. We have used a single AAV delivery vector to deliver a *RHO*-specific shRNA under the control of the H1 promoter and a resistant *Rho* gene under the control of the mouse opsin proximal promoter. We observed sustained protection of the retina (80% of the normal ERG response) up to 9 months post treatment with the combination vector [46].

MicroRNA: The limitations of shRNAs and siRNA have led to the utilization of artificial miRNAs, which are derived from a natural pre-miRNA backbone such as miR-30 or miR-155 (101-106). Artificial miRNAs, avoid toxicity even when longer dsRNA regions are employed [100-102]. The natural antisense sequence, found in the miRNA, is removed and replaced with the siRNA sequence of interest [103]. Several structural properties are also necessary for potency: these include appropriate 3' and 5' flanking regions and a mismatch bulge at positions +1 and +11-12 [104]. Unlike shRNAs, artificial miRNAs allow for expression from Pol II promoters and from within natural or artificial introns [105,106]. This allows for greater temporal and spatial expression and incorporation of the artificial miRNA into an mRNA coding sequence. Multiple artificial miRNAs strung together may target several genes or multiple sites of the same gene [106,107]. Tested in cell and mouse lines, artificial miRNAs




Figure 3. Gene suppression. **A:** Zinc finger artificial transcription factors (ZF-ATF) use suppressor transcription factors to silence gene transcription. **B:** Zinc finger nucleases (ZFN) causes a double-stranded break leading to correction of the mutation through recombination. **C:** miRNA and shRNA degrade the endogenous target transcript while sparing the introduced resistant mRNA (hardened) with an altered sequence. **D:** Ribozymes catalytically cleave the target transcript, but insertion of a guanosine at the target site dramatically reduces cleavage of the hardened target.

had fewer toxic effects and greater knockdown even when encoding the same siRNA as an equivalent shRNA when both were expressed from the U6 promoter [108-111]. Their effectiveness has also been studied in gene therapy and several disease models including HIV and cancer [111-114]. Mueller and colleagues recently demonstrated long-term prevention of the liver disease associated with a dominant mutation of α -1-antitrypsin using AAV delivery of a combination of concatenated artificial miRNAs and a resistant AAT cDNA [115].

RNA interference disadvantages: Overexpressed shRNAs have been shown to be toxic in the central nervous system and the liver [116]. This is possibly due to the saturation of exportin 5 and obstruction of the normal miRNA maturation process. These instances of shRNA-associated toxicity required a duplex region of greater than 20 bp, and shorter duplexes appear to be safe [117]. Ambati and colleagues have reported that administering siRNAs greater than 21 bp can actually lead to retinal degeneration in animal models, through Toll-like receptor-3 (TLR3), but TLR7 and TLR8 are more commonly accepted as mediating the innate immune response to dsRNA [118,119]. Other potential problems of shRNAs and artificial miRNAs arise from “off target” effects [100-102]. These can arise from base pairing to the

coding region or within the 3' UTR of an unintended target mRNA. Fifteen consecutive base pairs can stimulate the RNAi response (mRNA digestion), but as few as seven base pairs in the 3' UTR can inhibit translation via the miRNA pathway [120,121]. Double-stranded RNA such as siRNAs can also kindle non-specific antiviral defense mechanisms, leading to cell death [122].

Ribozymes: Ribozyme technology for gene therapy arose in the early 1990s but has not advanced as rapidly as RNAi, and no commercial ribozyme has been marketed despite considerable effort. Nevertheless, small ribozymes such as hammerheads and hairpins are relatively easy to engineer and can be effective RNA knockdown agents in cells and in tissues (Figure 3D). The cleavage site for a hammerhead ribozyme has only moderate requirements, targeting NUX, where N is any nucleotide and X is any base except G [123-125]. There are differences in activity based on the target triplet, with AUC being the best followed by GUC and UUC [123-125]. Specificity is typically achieved through 12–15 base pairs with the target RNA [123,124]. The target for a hairpin ribozyme is BNGUC, where B is any nucleotide but adenosine. Because base pairing of the ribozyme is not assisted by a protein complex, experimental verification of the availability of targets within the folded RNA is important [126,127].

Since base pairing for either hammerheads or hairpins occurs in two distinct regions, there are no long contiguous regions of dsRNA in either ribozyme, minimizing their potential to stimulate the interferon pathway, though cleavage of an unintended RNA is still a problem. Regions of base pairing with the target mRNA are short, and it is relatively easy to use silent base changes to produce a cleavage-resistant mRNA: one mismatch is sometimes sufficient. The potential of ribozymes in treating ADRP has already been demonstrated in tissue culture and in animal models [91,92,96,128-130]. Ribozyme delivery with AAV led to reduced cleavage of a “hardened” (i.e., resistant) *RHO* transgene, preservation of ERG a- and b-wave amplitudes, and preservation of retinal structure based on histology.

Zinc finger transcription factors: Zinc fingers (ZFs) are DNA-binding domains present in many transcription factors. A single zinc finger domain is composed of 30 amino acids forming a $\beta\alpha$ fold and recognizes a three to four base pair target [131,132]. The targets can overlap at the fourth position, as the fourth base is bound on the opposite DNA strand. To ensure specificity, at least 16–18 base pairs or six ZF modules are needed [132,133]. The zinc finger modules can then be linked to transcriptional regulatory domains, typically repressors, or to endonucleases.

ZFs linked to transcriptional regulators are termed zinc finger artificial transcription factors (ZF-ATFs; Figure 3A). With repressor domains, ZF-ATFs have been effective at suppressing endogenous rhodopsin expression from wild-type and mutant *Rho* in a P347S transgenic mouse model of ADRP [134]. Mussolino et al. used a Krüppel-associated box repressor domain to silence both alleles (mutant and wild-type) of *Rho* [135]. Although this method reduced the rate of photoreceptor loss, this technique should be coupled to a gene replacement for full therapeutic results. In this case, base changes in the promoter driving expression of *RHO* could be introduced to prevent recognition by the ZF-repressor. A convenient way to do this would be to use the *RHO* promoter from another species, e.g., mouse promoter driving human *RHO*.

Zinc finger nucleases: Zinc finger nucleases (ZFNs) provide a powerful tool capable of permanently and specifically altering the genomic DNA (Figure 3B). They are constructed using the DNA binding domains of two zinc finger modules dimerizing two subunits of the endonuclease domain of the nuclease FokI (or similar nuclease that cleaves downstream of its recognition domain) [133]. Each ZFN has a target sequence of about nine base pairs for a total recognition sequence of 18 bp. Cleavage of the target gene can lead to non-homologous end-joining to repair the chromosome or can lead to correction of the

mutated sequence either through homologous recombination with the sister chromosome or through recombination with an ectopically administered DNA fragment with the corrected (wild-type) sequence. Recombination was increased to 17% using ZFN in a human P23H *RHO* expressing cell line [136].

Transcription activator-like effector nucleases: Transcription activator-like effector nucleases, or TALENs, are reportedly easier to engineer than ZFNs and may supplant them in the molecular toolkit of gene therapists [137-139]. TALENs are produced by bacteria of the genus *Xanthomonas*. These proteins contain as many as 30 tandem repeats of a 33- to 35-amino-acid-sequence motif, but a pair of residues in each repeat allows for single nucleotide specificity. As with ZFNs, engineered TALENs include a FokI endonuclease domain to introduce a double-strand break in the target gene. The use of TALENs in targeted gene suppression has already been demonstrated by Wood and et al. in *C. elegans* [140].

Zinc finger and TALEN disadvantages: Before ZFNs or TALENs are used in humans, the potential side effects need to be addressed. First, ZFNs are not completely specific and can induce toxic nonspecific cleavage [141]. The lack of specificity is largely due to one of the ZFNs binding and forming a homodimer. To overcome the formation of homodimers in ZFNs, small amino acid changes have been made with complementary changes on the other ZFN [142]. These changes destabilize homodimers while not affecting heterodimers. Another research group has attached destabilizing moieties, such as ubiquitin and FKBP12 [143]. These adducts allow control of protein levels and stability through the use of protease inhibitors nor a small ligand that stabilizes FKBP12 [141,143]. TALENs exhibited neither toxicity or non-specific mutagenesis in yeast grown on glucose medium, though no test of genotoxicity has been reported in mammalian cells [138]. Optimization of these techniques as well as increased screening and redesigning of ZFNs or TALENS before clinical use will likely provide a powerful tool for future retinal gene therapy [131,133].

Additional pathways: Additional pathways to increase retinal survival include modification of the mammalian target of rapamycin (mTOR) pathway and delivery of molecular chaperones. The mTOR is a protein kinase regulated by various upstream signaling pathways. The level mTOR is upregulated in cones in some RP models, suggesting starvation for amino acids and/or glucose [144,145]. Administration of insulin to *rdl* mice led to a 50% increase in survival of cone photoreceptors [144].

Grp78 or Bip is an ER resident chaperone of the Hsp70 family. Although increased production of Bip is taken as a sign of ER stress, AAV delivery of Bip relieved ER stress and

protected photoreceptors in a P23H *RHO* transgenic model of ADRP [32]. Misfolded rhodopsin can also be cleared from the endoplasmic reticulum by the so-called ERAD pathway and VCP, a molecular chaperone involved in that pathway, may have therapeutic potential for treating ADRP [146]. As an alternative to gene therapy, pharmacologic chaperones have great potential as treatment for diseases such as ADRP that are associated with misfolded proteins [12,147].

Therapeutic delivery:

Viral mediated delivery—ADRP gene therapy has relied heavily on viral mediated delivery [148]. Lentivirus, adenovirus and AAV vectors have proven effective at delivering genes to the retina and RPE for ocular gene therapy [149]. Lentivirus delivers genes efficiently to the RPE, but AAV is probably the most versatile vector due to its wide range of host cells, DNA-based genome, no known pathogenicity, and many serotypes with differing tissue specificity [6,150-152]. Several methods have already been created for large-scale production of recombinant AAV (rAAV), and it is already in clinical trials for Leber congenital amaurosis (LCA) associated with mutations in RPE65 [153-158]. Due to these advantages, AAV has been used to develop treatments for many forms of retinal degeneration, including achromatopsia, retinoschisis, X-linked RP, recessive RP, and dominant RP [6,49,159-167]. AAV, however, can accommodate only a 4.7 kb insert. This limitation does not preclude most ADRP genes, neurotrophic factors, or small shRNA and miRNA [6]. Recombination between rAAV genomes in cells infected with two viruses can increase the delivery capacity of AAV, albeit at reduced efficiency [168]. For larger genes and promoters, lentiviral vectors can be used, as they offer the greater carrying capacity at 8 kb [1,148,169,170]. Helper-dependent adenoviral vectors have little remaining genetic material between the terminal repeats and therefore have a high capacity for inserts (about 35 kb) [48]. Vector production requires helper viruses that cannot be completely removed, so safety may be an issue. Another significant problem is that neither lentiviral vectors nor adenoviral vectors transduce photoreceptors efficiently, thus limiting the vectors' utility for treating ADRP. Modifying the lentiviral pseudotype has not improved photoreceptor transduction substantially [171,172]. Deletion of the RGD sequence in the penton base of Ad5 improved infection of photoreceptors, but transduction efficiency lags behind that of AAV5 or AAV8 [173]. A recently developed "gutted" version of Sendai virus has been used for RPE transduction in mice and rats, and this RNA virus may be particularly useful for rapid onset delivery of siRNA [174].

Disadvantages of viral delivery: Despite the clear advantages to viral vectors, all viruses have size limitations, differing degrees of immune response mediated by Müller cell activation, and inflammation [149,170,175]. The humoral response to viral infection can prevent readministration of the same virus serotype following intravitreal injection [176]. In addition, neutralizing antibodies to AAV resulting from current or previous infections may attenuate gene transfer and should preclude participation in a clinical trial. Due to the size of the particles and the blood-retinal barrier, ocular injections are used for retinal gene transfer. However, in neonatal mice systemic injection of AAV9 transduces the retina, though systemic injections are likely to elicit an immune response and to transfer genes to the spleen, lung, and liver. For these reasons, alternatives to viral vectors are being investigated [177].

Non-viral delivery: Gene transfer to photoreceptors with liposomes has been inefficient in animal models. In contrast, DNA delivery using several types of nanoparticles has had more success. Nanoparticles may circumvent many of the disadvantages to viral vectors including limited carrying capacity and the immunogenic response to viral capsid proteins. Gene and siRNA delivery has been shown in intestinal cells with the use of orally administered nanoparticles [178]. Additional success with nanoparticles has been demonstrated in the lungs and central nervous system [1,179]. Delivery of the nanoparticles may be aided by gene gun or electrotransfer, which have proven useful for ciliary muscles and the cornea; however, the gene gun is not suitable for gene transfer to the retina [149]. Electroporation produced lasting expression of GDNF and GFP in the retina [149,180]. Additionally, electroporation has been effective in cultured retinal cells and retinal explants, and electroporation has been used in animals for plasmid and siRNA delivery to the retina [93,181,182].

CK30-PEG nanoparticles have shown promise in mouse models of ADRP [183,184]. CK30-PEG nanoparticles are composed of poly-L-lysine coated with polyethylene glycol (PEG) moieties [183,184]. Together, these neutralize the negative charge of DNA, allowing for DNA compaction. PEG groups prolong circulation by preventing protein attachment and slow DNA degradation [183]. The carrying capacity has been tested up to 20 kb, four times larger than AAV, and provided robust gene expression [183]. Moreover, the gene activation was within hours, while AAV requires a minimum of 2 days. The size is only 8–20 nm, allowing passage through the tight junctions in the retina [183]. Injections of nanoparticles containing wild-type rds/peripherin (*Perph2*) in *Perph2*^{+/-} mice at postnatal day 5 mice led to protection of

the retina as demonstrated by IRBP and opsin expression out to 15 months [183]. Using either the IRBP promoter or the chicken beta actin promoter to drive rds/peripherin expression, *Perph2^{+/-}* mice showed increased ERG response and improved retinal structure [185]. Additional studies measured onset of luciferase and LacZ expression following retina and corneal nanoparticle delivery [186]. CK30-PEG showed no signs of an immunogenic response or of toxicity [1,187].

Disadvantages of non-viral delivery: Currently, nanoparticles have several disadvantages. Nanoparticles are typically degraded quickly in endosomes, and delivered genes may have a shorter duration of expression than viral vectors [186]. Long-term gene delivery has been reported using CK30-PEG nanoparticles [183-185], but these results must be replicated in other laboratories. Because the outer retina is not well perfused, nanoparticles may have a long residence time, and formulations containing gold or iron that may be suitable for gene delivery in larger organs may prove toxic in the retina [188]. In addition, some nanoparticles may induce light damage to the retina [189].

Future directions: The future of ocular gene therapy may not lie in any one treatment discussed above but in the combination of treatments. NTFs are effective at retarding photoreceptor loss, but the degeneration is only slowed, and a more permanent gene-directed treatment may be needed. NTFs could be used as an initial treatment to protect and slow photoreceptor loss. This approach would prove most useful in rapidly degenerating forms of ADRP. Second, a combination of ribozymes, miRNA, and/or shRNAs could be used to ensure sufficient suppression of the mutant allele. Third, advancements in ZFNs or TALENs to reduce toxic off-site cleavage will make these powerful tools for permanently correcting the mutant allele at the DNA level. This technology partnered with stem cell-based regenerative medicine may permit repair of a patient's own stem cells for replacing defective photoreceptors or RPE.

The use of self-complementary AAV and capsid modifications will improve AAV-mediated gene delivery [161,190,191]. Gene therapy using self-complementary AAV permits delivery of double-stranded DNA to shorten the onset of gene expression and increases transduction efficiency [192-197]. Capsid modification of AAV has also yielded improvements in transduction [177,190,198,199]. Because phosphorylation of surface tyrosine residues leads to degradation of AAV particles after infection, mutating certain tyrosines to phenylalanine increases productive infection. Although AAV serotypes 5 and 8 have been the vectors of choice for photoreceptors, the modified AAV8 (Y733F) has increased transduction efficiency [6,190,191,200].

Finally, nanoparticles hold a great potential for treating not just the eyes but also the entire central nervous system, as these particles have the ability to pass through the blood/central nervous system barriers, have low immunogenicity, and allow for large insert sizes. Although further research is needed, advances in nanoparticles may allow for topical or systemically delivered gene therapies to the retina.

ACKNOWLEDGMENTS

The authors acknowledge support by the Foundation Fighting Blindness, the Shaler Richardson endowment and by NIH grant T32 EY007132.

REFERENCES

1. Sung CH, Chuang JZ. The cell biology of vision. *J Cell Biol* 2010; 190:953-63. [PMID: 20855501].
2. Hamel CP. Cone rod dystrophies. *Orphanet J Rare Dis* 2007; 2:7-[PMID: 17270046].
3. Hamel C. Retinitis pigmentosa. *Orphanet J Rare Dis* 2006; 1:40-[PMID: 17032466].
4. Rakoczy EP, Kiel C, McKeone R, Stricher F, Serrano L. Analysis of disease-linked rhodopsin mutations based on structure, function, and protein stability calculations. *J Mol Biol* 2011; 405:584-606. [PMID: 21094163].
5. Bramall AN, Wright AF, Jacobson SG, McInnes RR. The genomic, biochemical, and cellular responses of the retina in inherited photoreceptor degenerations and prospects for the treatment of these disorders. *Annu Rev Neurosci* 2010; 33:441-72. [PMID: 20572772].
6. Dinculescu A, Glushakova L, Min SH, Hauswirth WW. Adeno-associated virus-vectored gene therapy for retinal disease. *Hum Gene Ther* 2005; 16:649-63. [PMID: 15960597].
7. Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, Hayes KC, Johnson CA, Anderson EJ, Gaudio AR, Willett WC, Schaefer EJ. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. *Arch Ophthalmol* 2004; 122:1297-305. [PMID: 15364708].
8. Krebs MP, Holden DC, Joshi P, Clark CL 3rd, Lee AH, Kaushal S. Molecular mechanisms of rhodopsin retinitis pigmentosa and the efficacy of pharmacological rescue. *J Mol Biol* 2010; 395:1063-78. [PMID: 19913029].
9. Tam LC, Kiang AS, Campbell M, Keaney J, Farrar GJ, Humphries MM, Kenna PF, Humphries P. Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90). *Hum Mol Genet* 2010; 19:4421-36. [PMID: 20817636].
10. Ohgane K, Dodo K, Hashimoto Y. Retinobenzaldehydes as proper-trafficking inducers of folding-defective P23H rhodopsin mutant responsible for retinitis pigmentosa. *Bioorg Med Chem* 2010; 18:7022-8. [PMID: 20805032].

11. Maeda T, Maeda A, Leahy P, Saperstein DA, Palczewski K. Effects of long-term administration of 9-cis-retinyl acetate on visual function in mice. *Invest Ophthalmol Vis Sci* 2009; 50:322-33. [PMID: 18708622].
12. Mendes HF, Zaccarini R, Cheetham ME. Pharmacological manipulation of rhodopsin retinitis pigmentosa. *Adv Exp Med Biol* 2010; 664:317-23. [PMID: 20238031].
13. Lee SY, Usui S, Zafar AB, Oveson BC, Jo YJ, Lu L, Masoudi S, Campochiaro PA. N-Acetylcysteine promotes long-term survival of cones in a model of retinitis pigmentosa. *J Cell Physiol* 2011; 226:1843-9. [PMID: 21506115].
14. Komeima K, Rogers BS, Campochiaro PA. Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. *J Cell Physiol* 2007; 213:809-15. [PMID: 17520694].
15. Obolensky A, Berenshtein E, Lederman M, Bulvik B, Alper-Pinus R, Yaul R, Deleon E, Chowers I, Chevion M, Banin E. Zinc-desferrioxamine attenuates retinal degeneration in the rd10 mouse model of retinitis pigmentosa. *Free Radic Biol Med* 2011; 51:1482-91. [PMID: 21824515].
16. Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. *CNS Drugs* 2002; 16:669-94. [PMID: 12269861].
17. Sisk RA. Valproic acid treatment may be harmful in non-dominant forms of retinitis pigmentosa. *Br J Ophthalmol* 2012; 96:1154-5. [PMID: 22581401].
18. Sandberg MA, Rosner B, Weigel-DiFranco C, Berson EL. Lack of scientific rationale for use of valproic acid for retinitis pigmentosa. *Br J Ophthalmol* 2011; 95:744. [PMID: 21131379].
19. Roof DJ, Adamian M, Hayes A. Rhodopsin accumulation at abnormal sites in retinas of mice with a human P23H rhodopsin transgene. *Invest Ophthalmol Vis Sci* 1994; 35:4049-62. [PMID: 7960587].
20. Chen YF, Wang IJ, Lin LL, Chen MS. Examining rhodopsin retention in endoplasmic reticulum and intracellular localization in vitro and in vivo by using truncated rhodopsin fragments. *J Cell Biochem* 2011; 112:520-30. [PMID: 21268073].
21. Murray AR, Fliesler SJ, Al-Ubaidi MR. Rhodopsin: the functional significance of asn-linked glycosylation and other post-translational modifications. *Ophthalmic Genet* 2009; 30:109-20. [PMID: 19941415].
22. Frederick JM, Krasnoperova NV, Hoffmann K, Church-Kopish J, Ruther K, Howes K, Lem J, Baehr W. Mutant rhodopsin transgene expression on a null background. *Invest Ophthalmol Vis Sci* 2001; 42:826-33. [PMID: 11222546].
23. Wen XH, Shen L, Brush RS, Michaud N, Al-Ubaidi MR, Gurevich VV, Hamm HE, Lem J, Dibenedetto E, Anderson RE, Makino CL. Overexpression of rhodopsin alters the structure and photoresponse of rod photoreceptors. *Biophys J* 2009; 96:939-50. [PMID: 19186132].
24. Mendes HF, van der Spuy J, Chapple JP, Cheetham ME. Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. *Trends Mol Med* 2005; 11:177-85. [PMID: 15823756].
25. Kang MJ, Ryoo HD. Suppression of retinal degeneration in *Drosophila* by stimulation of ER-associated degradation. *Proc Natl Acad Sci USA* 2009; 106:17043-8. [PMID: 19805114].
26. Kaushal S, Ridge KD, Khorana HG. Structure and function in rhodopsin: the role of asparagine-linked glycosylation. *Proc Natl Acad Sci USA* 1994; 91:4024-8. [PMID: 8171029].
27. Sakami S, Maeda T, Bereta G, Okano K, Golczak M, Sumaroka A, Roman AJ, Cideciyan AV, Jacobson SG, Palczewski K. Probing mechanisms of photoreceptor degeneration in a new mouse model of the common form of autosomal dominant retinitis pigmentosa due to P23H opsin mutations. *J Biol Chem* 2011; 286:10551-67. [PMID: 21224384].
28. Kaushal S, Khorana HG. Structure and function in rhodopsin. 7. Point mutations associated with autosomal dominant retinitis pigmentosa. *Biochemistry* 1994; 33:6121-8. [PMID: 8193125].
29. Tam BM, Moritz OL. Dark rearing rescues P23H rhodopsin-induced retinal degeneration in a transgenic *Xenopus laevis* model of retinitis pigmentosa: a chromophore-dependent mechanism characterized by production of N-terminally truncated mutant rhodopsin. *J Neurosci* 2007; 27:9043-53. [PMID: 17715341].
30. White DA, Fritz JJ, Hauswirth WW, Kaushal S, Lewin AS. Increased sensitivity to light-induced damage in a mouse model of autosomal dominant retinal disease. *Invest Ophthalmol Vis Sci* 2007; 48:1942-51. [PMID: 17460245].
31. Lin JH, Li H, Yasumura D, Cohen HR, Zhang C, Panning B, Shokat KM, Lavail MM, Walter P. IRE1 signaling affects cell fate during the unfolded protein response. *Science* 2007; 318:944-9. [PMID: 17991856].
32. Gorbatyuk MS, Knox T, LaVail MM, Gorbatyuk OS, Noorwez SM, Hauswirth WW, Lin JH, Muzyczka N, Lewin AS. Restoration of visual function in P23H rhodopsin transgenic rats by gene delivery of BiP/Grp78. *Proceedings of the National Academy of Sciences of the United States of America*. 107:5961-6.
33. Fletcher EL. Mechanisms of photoreceptor death during retinal degeneration. *Optom Vis Sci* 2010; 87:269-75. [PMID: 20019644].
34. Tam BM, Moritz OL. The role of rhodopsin glycosylation in protein folding, trafficking, and light-sensitive retinal degeneration. *J Neurosci* 2009; 29:15145-54. [PMID: 19955366].
35. Liu H, Wang M, Xia CH, Du X, Flannery JG, Ridge KD, Beutler B, Gong X. Severe retinal degeneration caused by a novel rhodopsin mutation. *Invest Ophthalmol Vis Sci* 2010; 51:1059-65. [PMID: 19741247].
36. Zhu L, Jang GF, Jastrzebska B, Filipek S, Pearce-Kelling SE, Aguirre GD, Stenkamp RE, Acland GM, Palczewski K. A naturally occurring mutation of the opsin gene (T4R) in dogs affects glycosylation and stability of the G protein-coupled receptor. *J Biol Chem* 2004; 279:53828-39. [PMID: 15459196].

37. Komáromy AM, Acland GM, Aguirre GD. Operating in the dark: a night-vision system for surgery in retinas susceptible to light damage. *Arch Ophthalmol* 2008; 126:714-7. [PMID: 18474785].
38. Zeiss CJ, Allore HG, Towle V, Tao W. CNTF induces dose-dependent alterations in retinal morphology in normal and rcd-1 canine retina. *Exp Eye Res* 2006; 82:395-404. [PMID: 16143329].
39. Cideciyan AV, Jacobson SG, Aleman TS, Gu D, Pearce-Kelling SE, Sumaroka A, Acland GM, Aguirre GD. In vivo dynamics of retinal injury and repair in the rhodopsin mutant dog model of human retinitis pigmentosa. *Proc Natl Acad Sci USA* 2005; 102:5233-8. [PMID: 15784735].
40. Hauck SM, Kinkl N, Deeg CA, Swiatek-de Lange M, Schoffmann S, Ueffing M. GDNF family ligands trigger indirect neuroprotective signaling in retinal glial cells. *Mol Cell Biol* 2006; 26:2746-57. [PMID: 16537917].
41. Ghosh F, Engelsberg K, English RV, Petters RM. Long-term neuroretinal full-thickness transplants in a large animal model of severe retinitis pigmentosa. *Graefes archive for clinical and experimental ophthalmology Albrecht Von Graefes Arch Klin Exp Ophthalmol* 2007; 245:835-46. .
42. Ross JW, Fernandez de Castro JP, Zhao J, Samuel M, Walters E, Rios C, Bray-Ward P, Jones BW, Marc RE, Wang W, Zhou L, Noel JM, McCall MA, DeMarco PJ, Prather RS, Kaplan HJ. Generation of an inbred miniature pig model of retinitis pigmentosa. *Invest Ophthalmol Vis Sci* 2012; 53:501-7. [PMID: 22247487].
43. Goto Y, Peachey NS, Ripps H, Naash MI. Functional abnormalities in transgenic mice expressing a mutant rhodopsin gene. *Invest Ophthalmol Vis Sci* 1995; 36:62-71. [PMID: 7822160].
44. Peachey NS, Ridder WH 3rd, Seeliger MW. Electrophysiologic assessment of the mouse visual system. *Doc Ophthalmol* 2007; 115:125-[PMID: 17823836].
45. Chadderton N, Millington-Ward S, Palfi A, O'Reilly M, Tuohy G, Humphries MM, Li T, Humphries P, Kenna PF, Farrar GJ. Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy. *Mol Ther* 2009; 17:593-9. [PMID: 19174761].
46. Mao H, Gorbatyuk MS, Rossmiller B, Hauswirth WW, Lewin AS. Long-term rescue of retinal structure and function by rhodopsin RNA replacement with a single adeno-associated viral vector in P23H RHO transgenic mice. *Hum Gene Ther* 2012; 23:356-66. [PMID: 22289036].
47. Prusky GT, Alam NM, Beekman S, Douglas RM. Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. *Invest Ophthalmol Vis Sci* 2004; 45:4611-6. [PMID: 15557474].
48. Kumar-Singh R, Chamberlain JS. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. *Hum Mol Genet* 1996; 5:913-21. [PMID: 8817325].
49. Pang JJ, Dai X, Boye SE, Barone I, Boye SL, Mao S, Everhart D, Dinculescu A, Liu L, Umino Y, Lei B, Chang B, Barlow R, Strettoi E, Hauswirth WW. Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa. *Mol Ther* 2011; 19:234-42. [PMID: 21139570].
50. Alexander JJ, Umino Y, Everhart D, Chang B, Min SH, Li Q, Timmers AM, Hawes NL, Pang JJ, Barlow RB, Hauswirth WW. Restoration of cone vision in a mouse model of achromatopsia. *Nat Med* 2007; 13:685-7. [PMID: 17515894].
51. Pearson RA, Barber AC, Rizzi M, Hippert C, Xue T, West EL, Duran Y, Smith AJ, Chuang JZ, Azam SA, Luhmann UF, Benucci A, Sung CH, Bainbridge JW, Carandini M, Yau KW, Sowden JC, Ali RR. Restoration of vision after transplantation of photoreceptors. *Nature* 2012; 485:99-103. [PMID: 22522934].
52. Ruggeri M, Wehbe H, Jiao S, Gregori G, Jockovich ME, Hackam A, Duan Y, Puliafito CA. In vivo three-dimensional high-resolution imaging of rodent retina with spectral-domain optical coherence tomography. *Invest Ophthalmol Vis Sci* 2007; 48:1808-14. [PMID: 17389515].
53. Gabriele ML, Ishikawa H, Schuman JS, Bilonick RA, Kim J, Kagemann L, Wollstein G. Reproducibility of spectral-domain optical coherence tomography total retinal thickness measurements in mice. *Invest Ophthalmol Vis Sci* 2010; 51:6519-23. [PMID: 20574022].
54. Huber G, Beck SC, Grimm C, Sahaboglu-Tekgoz A, Paquet-Durand F, Wenzel A, Humphries P, Redmond TM, Seeliger MW, Fischer MD. Spectral domain optical coherence tomography in mouse models of retinal degeneration. *Invest Ophthalmol Vis Sci* 2009; 50:5888-95. [PMID: 19661229].
55. Wang R, Jiang C, Ma J, Young MJ. Monitoring morphological changes in the retina of rhodopsin^{-/-} mice with spectral domain optical coherence tomography. *Invest Ophthalmol Vis Sci* 2012; 53:3967-72. [PMID: 22618589].
56. Hawes NL, Smith RS, Chang B, Davisson M, Heckenlively JR, John SW. Mouse fundus photography and angiography: a catalogue of normal and mutant phenotypes. *Mol Vis* 1999; 5:22-[PMID: 10493779].
57. Chang B, Hawes NL, Hurd RE, Wang J, Howell D, Davisson MT, Roderick TH, Nusinowitz S, Heckenlively JR. Mouse models of ocular diseases. *Vis Neurosci* 2005; 22:587-93. [PMID: 16332269].
58. Pang JJ, Chang B, Kumar A, Nusinowitz S, Noorwez SM, Li J, Rani A, Foster TC, Chiodo VA, Doyle T, Li H, Malhotra R, Teusner JT, McDowell JH, Min SH, Li Q, Kaushal S, Hauswirth WW. Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. *Mol Ther* 2006; 13:565-72. [PMID: 16223604].
59. Faktorovich EG, Steinberg RH, Yasumura D, Matthes MT, LaVail MM. Photoreceptor degeneration in inherited retinal dystrophy delayed by basic fibroblast growth factor. *Nature* 1990; 347:83-6. [PMID: 2168521].

60. L veillard T, Mohand-Said S, Lorentz O, Hicks D, Fintz AC, Clerin E, Simonutti M, Forster V, Cavusoglu N, Chalmel F, Dolle P, Poch O, Lambrou G, Sahel JA. Identification and characterization of rod-derived cone viability factor. *Nat Genet* 2004; 36:755-9. [PMID: 15220920].
61. L veillard T, Mohand-Said S, Fintz AC, Lambrou G, Sahel JA. The search for rod-dependent cone viability factors, secreted factors promoting cone viability. *Novartis Found Symp* 2004; 255:117-27. [PMID: 14750600].
62. Yang Y, Mohand-Said S, Danan A, Simonutti M, Fontaine V, Clerin E, Picaud S, L veillard T, Sahel JA. Functional cone rescue by RdCVF protein in a dominant model of retinitis pigmentosa. *Mol Ther* 2009; 17:787-95. [PMID: 19277021].
63. Caff  AR, Soderpalm AK, Holmqvist I, van Veen T. A combination of CNTF and BDNF rescues rd photoreceptors but changes rod differentiation in the presence of RPE in retinal explants. *Invest Ophthalmol Vis Sci* 2001; 42:275-82. [PMID: 11133879].
64. Yang PB, Seiler MJ, Aramant RB, Yan F, Mahoney MJ, Kitzes LM, Keirstead HS. Trophic factors GDNF and BDNF improve function of retinal sheet transplants. *Exp Eye Res* 2010; 91:727-38. [PMID: 20804751].
65. Tombran-Tink J, Shivaram SM, Chader GJ, Johnson LV, Bok D. Expression, secretion, and age-related downregulation of pigment epithelium-derived factor, a serpin with neurotrophic activity. *J Neurosci* 1995; 15:4992-5003. [PMID: 7623128].
66. Sugita Y, Becerra SP, Chader GJ, Schwartz JP. Pigment epithelium-derived factor (PEDF) has direct effects on the metabolism and proliferation of microglia and indirect effects on astrocytes. *J Neurosci Res* 1997; 49:710-8. [PMID: 9335258].
67. Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR, Bush RA. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. *Proc Natl Acad Sci USA* 2006; 103:3896-901. [PMID: 16505355].
68. Thanos CG, Bell WJ, O'Rourke P, Kauper K, Sherman S, Stabila P, Tao W. Sustained secretion of ciliary neurotrophic factor to the vitreous, using the encapsulated cell therapy-based NT-501 intraocular device. *Tissue Eng* 2004; 10:1617-22. [PMID: 15684670].
69. Bok D, Yasumura D, Matthes MT, Ruiz A, Duncan JL, Chapelow AV, Zolotukhin S, Hauswirth W, LaVail MM. Effects of adeno-associated virus-vectored ciliary neurotrophic factor on retinal structure and function in mice with a P216L rds/peripherin mutation. *Exp Eye Res* 2002; 74:719-35. [PMID: 12126945].
70. Schlichtenbrede FC, MacNeil A, Bainbridge JW, Tschernutter M, Thrasher AJ, Smith AJ, Ali RR. Intraocular gene delivery of ciliary neurotrophic factor results in significant loss of retinal function in normal mice and in the Prph2Rd2/Rd2 model of retinal degeneration. *Gene Ther* 2003; 10:523-7. [PMID: 12621456].
71. Li Y, Tao W, Luo L, Huang D, Kauper K, Stabila P, Lavail MM, Laties AM, Wen R. CNTF induces regeneration of cone outer segments in a rat model of retinal degeneration. *PLoS ONE* 2010; 5:e9495-[PMID: 20209167].
72. Liang FQ, Aleman TS, Dejneka NS, Dudus L, Fisher KJ, Maguire AM, Jacobson SG, Bennett J. Long-term protection of retinal structure but not function using RAAV.CNTF in animal models of retinitis pigmentosa. *Mol Ther* 2001; 4:461-72. [PMID: 11708883].
73. McGee Sanftner LH, Abel H, Hauswirth WW, Flannery JG. Glial cell line derived neurotrophic factor delays photoreceptor degeneration in a transgenic rat model of retinitis pigmentosa. *Mol Ther* 2001; 4:622-9. [PMID: 11735347].
74. Frasson M, Picaud S, L veillard T, Simonutti M, Mohand-Said S, Dreyfus H, Hicks D, Sabel J. Glial cell line-derived neurotrophic factor induces histologic and functional protection of rod photoreceptors in the rd/rd mouse. *Invest Ophthalmol Vis Sci* 1999; 40:2724-34. [PMID: 10509671].
75. Koeberle PD, Ball AK. Effects of GDNF on retinal ganglion cell survival following axotomy. *Vision Res* 1998; 38:1505-15. [PMID: 9667015].
76. Cheng H, Fu YS, Guo JW. Ability of GDNF to diminish free radical production leads to protection against kainate-induced excitotoxicity in hippocampus. *Hippocampus* 2004; 14:77-86. [PMID: 15058485].
77. Wu WC, Lai CC, Chen SL, Sun MH, Xiao X, Chen TL, Lin KK, Kuo SW, Tsao YP. Long-term safety of GDNF gene delivery in the retina. *Curr Eye Res* 2005; 30:715-22. [PMID: 16109652].
78. Yang PB, Seiler MJ, Aramant RB, Yan F, Mahoney MJ, Kitzes LM, Keirstead HS. Trophic factors GDNF and BDNF improve function of retinal sheet transplants. *Exp Eye Res* 2010; 91:727-38. [PMID: 20804751].
79. Yan Q, Wang J, Matheson CR, Urich JL. Glial cell line-derived neurotrophic factor (GDNF) promotes the survival of axotomized retinal ganglion cells in adult rats: comparison to and combination with brain-derived neurotrophic factor (BDNF). *J Neurobiol* 1999; 38:382-90. [PMID: 10022580].
80. Buch PK, MacLaren RE, Dur n Y, Balaggan KS, MacNeil A, Schlichtenbrede FC, Smith AJ, Ali RR. In contrast to AAV-mediated Cntf expression, AAV-mediated Gdnf expression enhances gene replacement therapy in rodent models of retinal degeneration. *Mol Ther* 2006; 14:700-9. [PMID: 16872907].
81. Rodger J, Drummond ES, Hellstrom M, Robertson D, Harvey AR. Long-term gene therapy causes transgene-specific changes in the morphology of regenerating retinal ganglion cells. *PLoS ONE* 2012; 7:e31061-[PMID: 22347429].
82. Xue W, Cojocaru RI, Dudley VJ, Brooks M, Swaroop A, Sarthy VP. Ciliary neurotrophic factor induces genes associated with inflammation and gliosis in the retina: a gene profiling study of flow-sorted, Muller cells. *PLoS ONE* 2011; 6:e20326-[PMID: 21637858].

83. Wen R, Tao W, Li Y, Sieving PA. CNTF and retina. *Prog Retin Eye Res* 2012; 31:136-51. [PMID: 22182585].
84. Touchard E, Heiduschka P, Berdugo M, Kowalczyk L, Bigey P, Chahory S, Gandolphe C, Jeanny JC, Behar-Cohen F. Non-viral gene therapy for GDNF production in RCS rat: the crucial role of the plasmid dose. *Gene Ther* 2012; 19:886-98. [PMID: 21993171].
85. Olsson JE, Gordon JW, Pawlyk BS, Roof D, Hayes A, Molday RS, Mukai S, Cowley GS, Berson EL, Dryja TP. Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa. *Neuron* 1992; 9:815-30. [PMID: 1418997].
86. Tan E, Wang Q, Quiambao AB, Xu X, Qtaishat NM, Peachey NS, Lem J, Fliesler SJ, Pepperberg DR, Naash MI, Al-Ubaidi MR. The relationship between opsin overexpression and photoreceptor degeneration. *Invest Ophthalmol Vis Sci* 2001; 42:589-600. [PMID: 11222515].
87. Lem J, Krasnoperova NV, Calvert PD, Kosaras B, Cameron DA, Nicolo M, Makino CL, Sidman RL. Morphological, physiological, and biochemical changes in rhodopsin knockout mice. *Proc Natl Acad Sci USA* 1999; 96:736-41. [PMID: 9892703].
88. Wilson JH, Wensel TG. The nature of dominant mutations of rhodopsin and implications for gene therapy. *Mol Neurobiol* 2003; 28:149-58. [PMID: 14576453].
89. Mao H, James T Jr, Schwein A, Shabashvili AE, Hauswirth WW, Gorbatyuk MS, Lewin AS. AAV delivery of wild-type rhodopsin preserves retinal function in a mouse model of autosomal dominant retinitis pigmentosa. *Hum Gene Ther* 2011; 22:567-75. [PMID: 21126223].
90. Lares MR, Rossi JJ, Ouellet DL. RNAi and small interfering RNAs in human disease therapeutic applications. *Trends Biotechnol* 2010; 28:570-9. [PMID: 20833440].
91. Gorbatyuk M, Justilien V, Liu J, Hauswirth WW, Lewin AS. Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery. *Vision Res* 2007; 47:1202-8. [PMID: 17292939].
92. Gorbatyuk M, Justilien V, Liu J, Hauswirth WW, Lewin AS. Preservation of photoreceptor morphology and function in P23H rats using an allele independent ribozyme. *Exp Eye Res* 2007; 84:44-52. [PMID: 17083931].
93. Kiang AS, Palfi A, Ader M, Kenna PF, Millington-Ward S, Clark G, Kennan A, O'reilly M, Tam LC, Aherne A, McNally N, Humphries P, Farrar GJ. Toward a gene therapy for dominant disease: validation of an RNA interference-based mutation-independent approach. *Mol Ther* 2005; 12:555-61. [PMID: 15967729].
94. Cashman SM, Binkley EA, Kumar-Singh R. Towards mutation-independent silencing of genes involved in retinal degeneration by RNA interference. *Gene Ther* 2005; 12:1223-8. [PMID: 15877050].
95. Smith AJ, Bainbridge JW, Ali RR. Prospects for retinal gene replacement therapy. *Trends in genetics TIG* 2009; 25:156-65. [PMID: 19303164].
96. Sullivan JM, Pietras KM, Shin BJ, Misasi JN. Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa. *Mol Vis* 2002; 8:102-13. [PMID: 11961505].
97. Millington-Ward S, Chadderton N, O'Reilly M, Palfi A, Goldmann T, Kilty C, Humphries M, Wolfrum U, Bennett J, Humphries P, Kenna PF, Farrar GJ. Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa. *Mol Ther* 2011; 19:642-9. [PMID: 21224835].
98. Li C, Xiao P, Gray SJ, Weinberg MS, Samulski RJ. Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins. *Proc Natl Acad Sci USA* 2011; 108:14258-63. [PMID: 21844342].
99. O'Reilly M, Palfi A, Chadderton N, Millington-Ward S, Ader M, Cronin T, Tuohy T, Auricchio A, Hildinger M, Tivnan A, McNally N, Humphries MM, Kiang AS, Humphries P, Kenna PF, Farrar GJ. RNA interference-mediated suppression and replacement of human rhodopsin in vivo. *Am J Hum Genet* 2007; 81:127-35. [PMID: 17564969].
100. Boudreau RL, Monteys AM, Davidson BL. Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. *RNA* 2008; 14:1834-44. [PMID: 18697922].
101. McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I, Gilmore BL, Burstein H, Peluso RW, Polisky B, Carter BJ, Davidson BL. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. *Proc Natl Acad Sci USA* 2008; 105:5868-73. [PMID: 18398004].
102. Beer S, Belloc DI, Lee JS, Komatsubara K, Wang LS, Koh H, Börner K, Storm TA, Davis CR, Kay MA, Felsner DW, Grimm D. Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. *Mol Ther* 2010; 18:161-70. [PMID: 19844192].
103. Zeng Y, Wagner EJ, Cullen BR. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. *Mol Cell* 2002; 9:1327-33. [PMID: 12086629].
104. Sin O, Mabilia P, Liu Y, Sun Y, Hu T, Liu Q, Guo D. Gene silencing efficiency and INF- β induction effects of splicing miRNA 155-based artificial miRNA with pre-miRNA stem-loop structures. *Biochem Genet* 2012; 50:112-21. [PMID: 22119863].
105. Liu Z, Sall A, Yang D. MicroRNA: An emerging therapeutic target and intervention tool. *Int J Mol Sci* 2008; 9:978-99. [PMID: 19325841].
106. Chung KH, Hart CC, Al-Bassam S, Avery A, Taylor J, Patel PD, Vojtek AB, Turner DL. Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. *Nucleic Acids Res* 2006; 34:e53-[PMID: 16614444].
107. Chen SC, Stern P, Guo Z, Chen J. Expression of multiple artificial microRNAs from a chicken miRNA126-based lentiviral vector. *PLoS ONE* 2011; 6:e22437-[PMID: 21789258].

108. Borel F, van Logtenstein R, Koornneef A, Maczuga P, Ritsema T, Petry H, van Deventer SJ, Jansen PL, Konstantinova P. In vivo knock-down of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial miRNAs. *J RNAi Gene Silencing*. 2011; 7:434-42. [PMID: 21769296].
109. Shan Z, Lin Q, Deng C, Li X, Huang W, Tan H, Fu Y, Yang M, Yu XY. An efficient method to enhance gene silencing by using precursor microRNA designed small hairpin RNAs. *Mol Biol Rep* 2009; 36:1483-9. [PMID: 18758992].
110. Furukawa N, Sakurai F, Katayama K, Seki N, Kawabata K, Mizuguchi H. Optimization of a microRNA expression vector for function analysis of microRNA. *J Control Release* 2011; 150:94-101. [PMID: 21146569].
111. Boden D, Pusch O, Silbermann R, Lee F, Tucker L, Ramratnam B. Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. *Nucleic Acids Res* 2004; 32:1154-8. [PMID: 14966264].
112. Hu T, Fu Q, Chen P, Ma L, Sin O, Guo D. Construction of an artificial MicroRNA expression vector for simultaneous inhibition of multiple genes in mammalian cells. *Int J Mol Sci* 2009; 10:2158-68. [PMID: 19564946].
113. Chen S, Ni M, Yu B, Lv T, Lu M, Gong F. Construction and identification of a human liver specific microRNA eukaryotic expression vector. *Cell Mol Immunol* 2007; 4:473-7. [PMID: 18163960].
114. Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. *Proc Natl Acad Sci USA* 2005; 102:13212-7. [PMID: 16141338].
115. Mueller C, Tang Q, Gruntman A, Blomenkamp K, Teckman J, Song L, Zamore PD, Flotte TR. Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles. *Mol Ther* 2012; 20:590-600. [PMID: 22252449].
116. Martin JN, Wolken N, Brown T, Dauer WT, Ehrlich ME, Gonzalez-Alegre P. Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design. *Gene Ther* 2011; 18:666-73. [PMID: 21368900].
117. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. *Nature* 2006; 441:537-41. [PMID: 16724069].
118. Kleinman ME, Kaneko H, Cho WG, Dridi S, Fowler BJ, Blandford AD, Albuquerque RJ, Hirano Y, Terasaki H, Kondo M, Fujita T, Ambati BK, Tarallo V, Gelfand BD, Bogdanovich S, Baffi JZ, Ambati J. Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3. *Mol Ther* 2012; 20:101-8. [PMID: 21988875].
119. Sioud M. RNA interference and innate immunity. *Adv Drug Deliv Rev* 2007; 59:153-63. [PMID: 17459518].
120. Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y, Baskerville S, Maksimova E, Robinson K, Karpilow J, Marshall WS, Khvorova A. 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. *Nat Methods* 2006; 3:199-204. [PMID: 16489337].
121. Grimm D, Kay MA. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? *J Clin Invest* 2007; 117:3633-41. [PMID: 18060021].
122. Robbins M, Judge A, Ambegia E, Choi C, Yaworski E, Palmer L, McClintock K, MacLachlan I. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. *Hum Gene Ther* 2008; 19:991-9. [PMID: 18713023].
123. Hauswirth WW, Lewin AS. Ribozyme uses in retinal gene therapy. *Prog Retin Eye Res* 2000; 19:689-710. [PMID: 11029552].
124. Amarzguioui M, Prydz H. Hammerhead ribozyme design and application. *Cell Mol Life Sci* 1998; 54:1175-202. [PMID: 9849614].
125. Norris JS, Hoel B, Voeks D, Maggouta F, Dahm M, Pan W, Clawson G. Design and testing of ribozymes for cancer gene therapy. *Adv Exp Med Biol* 2000; 465:293-301. [PMID: 10810634].
126. Abdelmaksoud HE, Yau EH, Zuker M, Sullivan JM. Development of lead hammerhead ribozyme candidates against human rod opsin mRNA for retinal degeneration therapy. *Exp Eye Res* 2009; 88:859-79. [PMID: 19094986].
127. Sullivan JM, Yau EH, Taggart RT, Butler MC, Kolniak TA. Bottlenecks in development of retinal therapeutic post-transcriptional gene silencing agents. *Vision Res* 2008; 48:453-69. [PMID: 17976683].
128. Lewin AS, Drenser KA, Hauswirth WW, Nishikawa S, Yasumura D, Flannery JG, LaVail MM. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. *Nat Med* 1998; 4:967-71. [PMID: 9701253].
129. Chakraborty D, Whalen P, Lewin AS, Naash MI. In vitro analysis of ribozyme-mediated knockdown of an ADRP associated rhodopsin mutation. *Adv Exp Med Biol* 2008; 613:97-106. [PMID: 18188933].
130. O'Neill B, Millington-Ward S, O'Reilly M, Tuohy G, Kiang AS, Kenna PF, Humphries P, Farrar GJ. Ribozyme-based therapeutic approaches for autosomal dominant retinitis pigmentosa. *Invest Ophthalmol Vis Sci* 2000; 41:2863-9. [PMID: 10967039].
131. Cornu TI, Cathomen T. Quantification of zinc finger nuclease-associated toxicity. *Methods Mol Biol* 2010; 649:237-45. [PMID: 20680838].
132. Mussolino C, Sanges D, Marrocco E, Bonetti C, Di Vicino U, Marigo V, Auricchio A, Meroni G, Surace EM. Zinc-finger-based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa. *EMBO Mol Med*. 2011; 3:118-28. [PMID: 21268285].
133. Cradick TJ, Ambrosini G, Iseli C, Bucher P, McCaffrey AP. ZFN-site searches genomes for zinc finger nuclease target

- sites and off-target sites. *BMC Bioinformatics* 2011; 12:152-[\[PMID: 21569489\]](#).
134. Mussolino C, Sanges D, Marrocco E, Bonetti C, Di Vicino U, Marigo V, Auricchio A, Meroni G, Surace EM. Zinc-finger-based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa. *EMBO Mol Med*. 2011; 3:118-28. [\[PMID: 21268285\]](#).
135. Otteson DC, Lai H, Liu Y, Zack DJ. Zinc-finger domains of the transcriptional repressor KLF15 bind multiple sites in rhodopsin and IRBP promoters including the CRS-1 and G-rich repressor elements. *BMC Mol Biol* 2005; 6:15-[\[PMID: 15963234\]](#).
136. Greenwald DL, Cashman SM, Kumar-Singh R. Engineered zinc finger nuclease-mediated homologous recombination of the human rhodopsin gene. *Invest Ophthalmol Vis Sci* 2010; 51:6374-80. [\[PMID: 20671268\]](#).
137. Christian M, Cermak T, Doyle EL, Schmidt C, Zhang F, Hummel A, Bogdanove AJ, Voytas DF. Targeting DNA double-strand breaks with TAL effector nucleases. *Genetics* 2010; 186:757-61. [\[PMID: 20660643\]](#).
138. Li T, Huang S, Zhao X, Wright DA, Carpenter S, Spalding MH, Weeks DP, Yang B. Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes. *Nucleic Acids Res* 2011; 39:6315-25. [\[PMID: 21459844\]](#).
139. Cermak T, Doyle EL, Christian M, Wang L, Zhang Y, Schmidt C, Baller JA, Somia NV, Bogdanove AJ, Voytas DF. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. *Nucleic Acids Res* 2011; 39:e82-[\[PMID: 21493687\]](#).
140. Wood AJ, Lo TW, Zeitler B, Pickle CS, Ralston EJ, Lee AH, Amora R, Miller JC, Leung E, Meng X, Zhang L, Rebar EJ, Gregory PD, Urnov FD, Meyer BJ. Targeted genome editing across species using ZFNs and TALENs. *Science* 2011; 333:307-[\[PMID: 21700836\]](#).
141. Carroll D. Progress and prospects: zinc-finger nucleases as gene therapy agents. *Gene Ther* 2008; 15:1463-8. [\[PMID: 18784746\]](#).
142. Miller JC, Holmes MC, Wang J, Guschin DY, Lee YL, Rupniewski I, Beausejour CM, Waite AJ, Wang NS, Kim KA, Gregory PD, Pabo CO, Rebar EJ. An improved zinc-finger nuclease architecture for highly specific genome editing. *Nat Biotechnol* 2007; 25:778-85. [\[PMID: 17603475\]](#).
143. Pruett-Miller SM, Reading DW, Porter SN, Porteus MH. Attenuation of zinc finger nuclease toxicity by small-molecule regulation of protein levels. *PLoS Genet* 2009; 5:e1000376-[\[PMID: 19214211\]](#).
144. Punzo C, Kornacker K, Cepko CL. Stimulation of the insulin/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa. *Nat Neurosci* 2009; 12:44-52. [\[PMID: 19060896\]](#).
145. Zhao C, Yasumura D, Li X, Matthes M, Lloyd M, Nielsen G, Ahern K, Snyder M, Bok D, Dunaief JL, LaVail MM, Vollrath D. mTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice. *J Clin Invest* 2011; 121:369-83. [\[PMID: 21135502\]](#).
146. Griciuc A, Aron L, Piccoli G, Ueffing M. Clearance of Rhodopsin(P23H) aggregates requires the ERAD effector VCP. *Biochim Biophys Acta* 2010; 1803:424-34. [\[PMID: 20097236\]](#).
147. Noorwez SM, Ostrov DA, McDowell JH, Krebs MP, Kaushal S. A high-throughput screening method for small-molecule pharmacologic chaperones of misfolded rhodopsin. *Invest Ophthalmol Vis Sci* 2008; 49:3224-30. [\[PMID: 18378578\]](#).
148. Han Z, Conley SM, Naash MI. AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects. *Invest Ophthalmol Vis Sci* 2011; 52:3051-9. [\[PMID: 21558483\]](#).
149. Bloquel C, Bourges JL, Touchard E, Berdugo M, BenEzra D, Behar-Cohen F. Non-viral ocular gene therapy: potential ocular therapeutic avenues. *Adv Drug Deliv Rev* 2006; 58:1224-42. [\[PMID: 17095114\]](#).
150. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, Samulski RJ. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. *J Virol* 2002; 76:791-801. [\[PMID: 11752169\]](#).
151. Doi K, Hargitai J, Kong J, Tsang SH, Wheatley M, Chang S, Goff S, Gouras P. Lentiviral transduction of green fluorescent protein in retinal epithelium: evidence of rejection. *Vision Res* 2002; 42:551-8. [\[PMID: 11853772\]](#).
152. van Adel BA, Kostic C, Deglon N, Ball AK, Arsenijevic Y. Delivery of ciliary neurotrophic factor via lentiviral-mediated transfer protects axotomized retinal ganglion cells for an extended period of time. *Hum Gene Ther* 2003; 14:103-15. [\[PMID: 12614562\]](#).
153. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. *Curr Top Microbiol Immunol* 1992; 158:97-129. [\[PMID: 1316261\]](#).
154. Grimm D, Kay MA, Kleinschmidt JA. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. *Mol Ther* 2003; 7:839-50. [\[PMID: 12788658\]](#).
155. Peden CS, Burger C, Muzyczka N, Mandel RJ. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. *J Virol* 2004; 78:6344-59. [\[PMID: 15163728\]](#).
156. Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, Reier PJ, Mandel RJ, Muzyczka N. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. *Mol Ther* 2004; 10:302-17. [\[PMID: 15294177\]](#).
157. Stieger K, Lorenz B. Gene therapy for vision loss—recent developments. *Discov Med* 2010; 10:425-33. [\[PMID: 21122474\]](#).

158. Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, Boye SL, Windsor EA, Conlon TJ, Sumaroka A, Pang JJ, Roman AJ, Byrne BJ, Jacobson SG. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. *Hum Gene Ther* 2009; 20:999-1004. [PMID: 19583479].
159. Sun X, Pawlyk B, Xu X, Liu X, Bulgakov OV, Adamian M, Sandberg MA, Khani SC, Tan MH, Smith AJ, Ali RR, Li T. Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations. *Gene Ther* 2010; 17:117-31. [PMID: 19710705].
160. Dinculescu A, Streicher J, Zenteno JC, Aleman TS, Schwartz SB, Huang WC, Roman AJ, Sumaroka A, Li Q, Deng WT, Min SH, Chiodo VA, Neeley A, Liu X, Shu X, Matias-Florentino M, Buentello-Volante B, Boye SL, Cideciyan AV, Hauswirth WW, Jacobson SG. Gene therapy for retinitis pigmentosa caused by MFRP mutations: human phenotype and preliminary proof of concept. *Hum Gene Ther* 2012; 23:367-76. [PMID: 22142163].
161. Mussolino C, della Corte M, Rossi S, Viola F, Di Vicino U, Marrocco E, Neglia S, Doria M, Testa F, Giovannoni R, Crasta M, Giunti M, Villani E, Lavitrano M, Bacci ML, Ratiaglia R, Simonelli F, Auricchio A, Surace EM. AAV-mediated photoreceptor transduction of the pig cone-enriched retina. *Gene Ther* 2011; 18:637-45. [PMID: 21412286].
162. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR. Effect of gene therapy on visual function in Leber's congenital amaurosis. *N Engl J Med* 2008; 358:2231-9. [PMID: 18441371].
163. Cideciyan AV, Aleman TS, Boye SL, Schwartz SB, Kaushal S, Roman AJ, Pang JJ, Sumaroka A, Windsor EA, Wilson JM, Flotte TR, Fishman GA, Heon E, Stone EM, Byrne BJ, Jacobson SG, Hauswirth WW. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. *Proc Natl Acad Sci USA* 2008; 105:15112-7. [PMID: 18809924].
164. Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, Boye SL, Windsor EA, Conlon TJ, Sumaroka A, Roman AJ, Byrne BJ, Jacobson SG. Vision 1 year after gene therapy for Leber's congenital amaurosis. *N Engl J Med* 2009; 361:725-7. [PMID: 19675341].
165. Dejneka NS, Surace EM, Aleman TS, Cideciyan AV, Lyubarsky A, Savchenko A, Redmond TM, Tang W, Wei Z, Rex TS, Glover E, Maguire AM, Pugh EN Jr, Jacobson SG, Bennett J. In utero gene therapy rescues vision in a murine model of congenital blindness. *Mol Ther* 2004; 9:182-8. [PMID: 14759802].
166. Komáromy AM, Alexander JJ, Cooper AE, Chiodo VA, Glushakova LG, Acland GM, Hauswirth WW, Aguirre GD. Targeting gene expression to cones with human cone opsin promoters in recombinant AAV. *Gene Ther* 2008; 15:1049-55. [PMID: 18337838].
167. Park TK, Wu Z, Kjellstrom S, Zeng Y, Bush RA, Sieving PA, Colosi P. Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rsl-KO mouse. *Gene Ther* 2009; 16:916-26. [PMID: 19458650].
168. Lai Y, Yue Y, Duan D. Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb. *Mol Ther* 2010; 18:75-9. [PMID: 19904238].
169. Tosi J, Sancho-Pelluz J, Davis RJ, Hsu CW, Wolpert KV, Sengillo JD, Lin CS, Tsang SH. Lentivirus-mediated expression of cDNA and shRNA slows degeneration in retinitis pigmentosa. *Exp Biol Med (Maywood)* 2011; 236:1211-7. [PMID: 21885480].
170. Kay MA. State-of-the-art gene-based therapies: the road ahead. *Nat Rev Genet* 2011; 12:316-28. [PMID: 21468099].
171. Auricchio A, Kobinger G, Anand V, Hildinger M, O'Connor E, Maguire AM, Wilson JM, Bennett J. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. *Hum Mol Genet* 2001; 10:3075-81. [PMID: 11751689].
172. Balaggan KS, Binley K, Esapa M, Iqbal S, Askham Z, Kan O, Tschernutter M, Bainbridge JW, Naylor S, Ali RR. Stable and efficient intraocular gene transfer using pseudotyped ELAV lentiviral vectors. *J Gene Med* 2006; 8:275-85. [PMID: 16299834].
173. Sweigard JH, Cashman SM, Kumar-Singh R. Adenovirus vectors targeting distinct cell types in the retina. *Invest Ophthalmol Vis Sci* 2010; 51:2219-28. [PMID: 19892875].
174. Murakami Y, Ikeda Y, Yonemitsu Y, Tanaka S, Kondo H, Okano S, Kohno R, Miyazaki M, Inoue M, Hasegawa M, Ishibashi T, Sueishi K. Newly-developed Sendai virus vector for retinal gene transfer: reduction of innate immune response via deletion of all envelope-related genes. *J Gene Med* 2008; 10:165-76. [PMID: 18074401].
175. Lowenstein PR, Mandel RJ, Xiong WD, Kroeger K, Castro MG. Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. *Curr Gene Ther* 2007; 7:347-60. [PMID: 17979681].
176. Li Q, Miller R, Han PY, Pang J, Dinculescu A, Chiodo V, Hauswirth WW. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. *Mol Vis* 2008; 14:1760-9. [PMID: 18836574].
177. Dalkara D, Byrne LC, Lee T, Hoffmann NV, Schaffer DV, Flannery JG. Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9. *Gene Ther* 2012; 19:176-81. [PMID: 22011645].
178. Xu J, Ganesh S, Amiji M. Non-condensing polymeric nanoparticles for targeted gene and siRNA delivery. *Int J Pharm* 2012; 427:21-34. [PMID: 21621597].
179. Yurek DM, Fletcher AM, Smith GM, Seroogy KB, Ziady AG, Molter J, Kowalczyk TH, Padegimas L, Cooper MJ. Long-term transgene expression in the central nervous system using DNA nanoparticles. *Mol Ther* 2009; 17:641-50. [PMID: 19223866].

180. Ishikawa H, Takano M, Matsumoto N, Sawada H, Ide C, Mimura O, Dezawa M. Effect of GDNF gene transfer into axotomized retinal ganglion cells using in vivo electroporation with a contact lens-type electrode. *Gene Ther* 2005; 12:289-98. [PMID: 15616607].
181. Matsuda T, Cepko CL. Electroporation and RNA interference in the rodent retina in vivo and in vitro. *Proc Natl Acad Sci USA* 2004; 101:16-22. [PMID: 14603031].
182. Sanuki R, Onishi A, Koike C, Muramatsu R, Watanabe S, Muranishi Y, Irie S, Uneo S, Koyasu T, Matsui R, Cherasse Y, Urade Y, Watanabe D, Kondo M, Yamashita T, Furukawa T. miR-124a is required for hippocampal axogenesis and retinal cone survival through Lhx2 suppression. *Nat Neurosci* 2011; 14:1125-34. [PMID: 21857657].
183. Conley SM, Naash MI. Nanoparticles for retinal gene therapy. *Prog Retin Eye Res* 2010; 29:376-97. [PMID: 20452457].
184. Kimura T, Nibe Y, Funamoto S, Okada M, Furuzono T, Ono T, Yoshizawa H, Fujisato T, Nam K, Kishida A. Preparation of a Nanoscaled Poly(vinyl alcohol)/Hydroxyapatite/DNA Complex Using High Hydrostatic Pressure Technology for In Vitro and In Vivo Gene Delivery. *J Drug Deliv* 2011; 2011:962743-[PMID: 21773048].
185. Cai X, Nash Z, Conley SM, Fliesler SJ, Cooper MJ, Naash MI. A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. *PLoS ONE* 2009; 4:e5290-[PMID: 19390689].
186. Binder C, Read SP, Cashman SM, Kumar-Singh R. Nuclear targeted delivery of macromolecules to retina and cornea. *J Gene Med* 2011; 13:158-70. [PMID: 21344542].
187. Ding XQ, Quiambao AB, Fitzgerald JB, Cooper MJ, Conley SM, Naash MI. Ocular delivery of compacted DNA-nanoparticles does not elicit toxicity in the mouse retina. *PLoS ONE* 2009; 4:e7410-[PMID: 19823583].
188. Jo DH, Lee TG, Kim JH. Nanotechnology and nanotoxicology in retinopathy. *Int J Mol Sci* 2011; 12:8288-301. [PMID: 22174664].
189. Wielgus AR, Roberts JE. Retinal Photodamage by Endogenous and Xenobiotic Agents. *Photochem Photobiol* 2012; xx:xx-xx. [PMID: 22582903].
190. Li M, Jayandharan GR, Li B, Ling C, Ma W, Srivastava A, Zhong L. High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy. *Hum Gene Ther* 2010; 21:1527-43. [PMID: 20507237].
191. Surace EM, Auricchio A. Versatility of AAV vectors for retinal gene transfer. *Vision Res* 2008; 48:353-9. [PMID: 17923143].
192. McCarty DM. Self-complementary AAV vectors; advances and applications. *Mol Ther* 2008; 16:1648-56. [PMID: 18682697].
193. Pang J, Boye SE, Lei B, Boye SL, Everhart D, Ryals R, Umino Y, Rohrer B, Alexander J, Li J, Dai X, Li Q, Chang B, Barlow R, Hauswirth WW. Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency. *Gene Ther* 2010; 17:815-26. [PMID: 20237510].
194. Kong F, Li W, Li X, Zheng Q, Dai X, Zhou X, Boye SL, Hauswirth WW, Qu J, Pang JJ. Self-complementary AAV5 vector facilitates quicker transgene expression in photoreceptor and retinal pigment epithelial cells of normal mouse. *Exp Eye Res* 2010; 90:546-54. [PMID: 20138034].
195. Koilkonda RD, Hauswirth WW, Guy J. Efficient expression of self-complementary AAV in ganglion cells of the ex vivo primate retina. *Mol Vis* 2009; 15:2796-802. [PMID: 20019878].
196. Gray SJ, Foti SB, Schwartz JW, Bachaboina L, Taylor-Blake B, Coleman J, Ehlers MD, Zylka MJ, McCown TJ, Samulski RJ. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. *Hum Gene Ther* 2011; 22:1143-53. [PMID: 21476867].
197. Simons DL, Boye SL, Hauswirth WW, Wu SM. Gene therapy prevents photoreceptor death and preserves retinal function in a Bardet-Biedl syndrome mouse model. *Proc Natl Acad Sci USA* 2011; 108:6276-81. [PMID: 21444805].
198. Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M, Herzog RW, Zolotukhin I, Warrington KH Jr, Weigel-Van Aken KA, Hobbs JA, Zolotukhin S, Muzyczka N, Srivastava A. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. *Proc Natl Acad Sci USA* 2008; 105:7827-32. [PMID: 18511559].
199. Zhong L, Li B, Jayandharan G, Mah CS, Govindasamy L, Agbandje-McKenna M, Herzog RW, Weigel-Van Aken KA, Hobbs JA, Zolotukhin S, Muzyczka N, Srivastava A. Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. *Virology* 2008; 381:194-202. [PMID: 18834608].
200. Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R, Wang L, Castle MJ, Maguire AC, Grant R, Wolfe JH, Wilson JM, Bennett J. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. *Sci Transl Med* 2011; 3:88ra54-[PMID: 21697530].

Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China. The print version of this article was created on 6 October 2012. This reflects all typographical corrections and errata to the article through that date. Details of any changes may be found in the online version of the article.